Abstract
Background: Angiotensin-converting enzyme inhibitor-induced angioedema (ACEi-AE) is the most frequent drug-induced angioedema. The aim of this study was to evaluate potential biomarkers for the detection of the risk to develop an ACEi-AE. Methods: Adult patients who started antihypertensive treatment with ramipril were included and followed up for 4-6 weeks. At baseline, 3 days, and 4-6 weeks after onset of therapy, blood samples were obtained. Results: Twenty-four patients could be enrolled. The thromboxane values were very heterogeneous, and none of the group differences observed was statistically significant. The values obtained for 6-keto-prostaglandin F1α (6-keto-PGF<sub>1α</sub>) showed a statistically significant increase with 10 mg/day doses under ramipril therapy. Conclusions: In this small patient population, it could be shown that determination of 6-keto-PGF<sub>1α</sub> is feasible. It may prove to be a valuable blood marker for assessing the risk of developing ACEi-AE.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
